oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Recent Posts
Contact
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
Jena Biotechnology Company Files for Insolvency
Press ReleasesJena, Thuringia, March 31, 2025. Jena-based Oncgnostics GmbH has filed for insolvency. The Gera District Court has ordered and appointed lawyer Kai Dellit from the law firm hww hermann wienberg […]
Methylation Tests in Cervical Cancer Screening Could Reduce Invasive Procedures up to 75%
Press ReleasesPorto / Jena, November 26, 2024 – Methylation tests could significantly increase the accuracy of cervical cancer screening and reduce referrals for colposcopy, which would, in turn, put less strain […]
Methylation Testing for Tumor Detection: A Non-Invasive Alternative to Standard Diagnostics
Press ReleasesJena / Düsseldorf, November 7, 2024 – Molecular biological diagnostics offer a non-invasive alternative for cancer detection. oncgnostics GmbH will demonstrate this in Düsseldorf at MEDICA, one of the world’s […]
Oncgnostics expands international distribution
Press ReleasesJena, July 22 – Oncgnostics GmbH signs an agreement with Seegene Germany GmbH for the international distribution of its own tests. Dr. Alfred Hansel, Managing Director of Oncgnostics: “The agreement […]
Psychological stress in cervical cancer tabood
Press ReleasesMedia study: A recent media study by Oncgnostics GmbH shows that, although the general media report on the topic of cervical cancer, they do not address the associated psychological stress […]
Molecular biological cancer diagnostics close gaps in cancer screening
Press ReleasesTwo tests for cervical cancer with different objectives in cervical cancer screening Liquid biopsy for rapid and gentle diagnosis of head and neck tumours Current studies: GynTect DNA methylation test […]
Hong Kong firm invests in Jena-based Oncgnostics GmbH
Press ReleasesJena, September 05, 2023. The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a seven-digit Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics has developed the cancer […]
Cancer diagnostics of the future thanks to highly informative biomarkers
Press Releasesoncgnostics at Medica 2022: Cervical cancer screening test conquers China Establishing early detection of head and neck tumours First study results for screening test for vulva and vaginal cancer At […]
German oncgnostics GmbH‘s innovation in the area of cervical cancer diagnostics now also available in China
Press ReleasesGynTect receives approval in China Jena, August 25, 2022 – The cervical cancer screening test GynTect is now available to physicians and patients in China, the world’s most populous country. […]
PCR test detects cervical precancerous lesions
Blog, Press ReleasesJena, Germany, May 25th 2022 – May 28 marks the 35th International Day of Action for Women’s Health. One “female” disease that should no longer exist due to the availability […]